The cost-effectiveness analysis of initiating HIV/AIDS treatment with efavirenz-based regimens compared with nevirapine-based regimens in Thailand.
Article
in English
| IMSEAR
| ID: sea-38822
ABSTRACT
OBJECTIVES:
The aim of this study is to evaluate the cost-utility of the treatment, starting with EFZ-based therapy, compared with NVP-based therapy in Thai HIV/AIDS patients. MATERIAL ANDMETHOD:
The study adopted a health care provider perspective. A probabilistic Markov model was applied to Thai HIV/AIDS patients aged 15 to 65 years. Input parameters were extracted from a cohort study of four regional hospitals. The study explored the effects of uncertainty around input parameters.RESULTS:
For those patients with a different baseline CD4, initial therapy using EFZ-based regimens was the preferable choice for all subgroups. Given a maximum acceptable willingness to pay (WTP) threshold of 300,000 Baht/DALY averted starting with EFZ-based regimens was cost-effective for patients with a baseline CD4 count less than 250 cells/mm3 and in all patient age groups, except those who were 20 years old.CONCLUSIONS:
The results suggest that starting with EFZ-based regimens was the preferable choice and it should be used as the first line regimen for Thai HIV/AIDS patients.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Thailand
/
Aged
/
Female
/
Humans
/
Male
/
HIV Infections
/
Probability
/
Cohort Studies
/
Markov Chains
/
Adolescent
Type of study:
Etiology study
/
Health economic evaluation
/
Incidence study
/
Observational study
/
Prognostic study
/
Risk factors
Country/Region as subject:
Asia
Language:
English
Year:
2008
Type:
Article
Similar
MEDLINE
...
LILACS
LIS